open access

Vol 14, No 3 (2019)
Original Papers
Published online: 2019-07-04
Get Citation

Sinus rhythm recovery in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants is safe without transoesophageal echocardiography evaluation — a preliminary report

Anna Szpotowicz, Iwona Gorczyca, Małgorzata Krzciuk, Beata Wożakowska -Kapłon
DOI: 10.5603/FC.2019.0054
·
Folia Cardiologica 2019;14(3):230-234.

open access

Vol 14, No 3 (2019)
Original Papers
Published online: 2019-07-04

Abstract

Introduction. Atrial fibrillation (AF) is the most common type of supraventricular arrhythmia. Electrical cardioversion is a non-pharmacological method of restoring sinus rhythm in AF patients. The role of transoesophageal echocardiography (TEE) in patients subjected to electrical cardioversion has not yet been fully established. The objective of this study was to assess the safety of electrical cardioversion procedures in AF patients who had received novel oral anticoagulants for at least 21 days prior to the procedure, and in whom electrical cardioversion was carried out without previous TEE examination. Material and methods. The study population consisted of 132 patients receiving non-vitamin K antagonist oral anticoagulants (NOACs) and subjected to electrical cardioversion procedures at a district hospital cardiology department. Patients with valvular AF and patients receiving NOACs in an irregular fashion were excluded from the study. The incidence of thromboembolic and haemorrhagic complications was assessed over a 30-day follow-up period. Results. In a group of 132 patients treated with NOACs, rivaroxaban was used in 65 (49.2%) patients, dabigatran was used in 62 (47.0%) patients, and apixaban was used in five (3.8%) patients. No thromboembolic or haemorrhagic complications were observed in the study group over the hospitalisation period or the 30-day follow-up period. Conclusions. NOACs are effective and safe in the premedication of AF patients prior to electrical cardioversion procedures. Electrical cardioversion without prior TEE is a safe method of managing patients receiving regular premedication with NOACs for at least 21 days before a sinus rhythm restoration procedure.

Abstract

Introduction. Atrial fibrillation (AF) is the most common type of supraventricular arrhythmia. Electrical cardioversion is a non-pharmacological method of restoring sinus rhythm in AF patients. The role of transoesophageal echocardiography (TEE) in patients subjected to electrical cardioversion has not yet been fully established. The objective of this study was to assess the safety of electrical cardioversion procedures in AF patients who had received novel oral anticoagulants for at least 21 days prior to the procedure, and in whom electrical cardioversion was carried out without previous TEE examination. Material and methods. The study population consisted of 132 patients receiving non-vitamin K antagonist oral anticoagulants (NOACs) and subjected to electrical cardioversion procedures at a district hospital cardiology department. Patients with valvular AF and patients receiving NOACs in an irregular fashion were excluded from the study. The incidence of thromboembolic and haemorrhagic complications was assessed over a 30-day follow-up period. Results. In a group of 132 patients treated with NOACs, rivaroxaban was used in 65 (49.2%) patients, dabigatran was used in 62 (47.0%) patients, and apixaban was used in five (3.8%) patients. No thromboembolic or haemorrhagic complications were observed in the study group over the hospitalisation period or the 30-day follow-up period. Conclusions. NOACs are effective and safe in the premedication of AF patients prior to electrical cardioversion procedures. Electrical cardioversion without prior TEE is a safe method of managing patients receiving regular premedication with NOACs for at least 21 days before a sinus rhythm restoration procedure.
Get Citation

Keywords

TEE; electrical cardioversion; NOAC

About this article
Title

Sinus rhythm recovery in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants is safe without transoesophageal echocardiography evaluation — a preliminary report

Journal

Folia Cardiologica

Issue

Vol 14, No 3 (2019)

Pages

230-234

Published online

2019-07-04

DOI

10.5603/FC.2019.0054

Bibliographic record

Folia Cardiologica 2019;14(3):230-234.

Keywords

TEE
electrical cardioversion
NOAC

Authors

Anna Szpotowicz
Iwona Gorczyca
Małgorzata Krzciuk
Beata Wożakowska -Kapłon

References (14)
  1. Prystowsky EN, Benson D, Fuster V, et al. Management of patients with atrial fibrillation. A statestment for healthcare professionals from the subcommittee on electrocardiography and electrophysiology. American Heart Association. Circulation. 1996; 93(6): 1262–1277.
  2. Fuster V, Rydén L, Cannom D, et al. ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration with the North American Society of Pacing and Electrophysiology. Circulation. 2001; 104(17): 2118–2150.
  3. Prevost JL, Battelli F. Sur quelques effets des decharges electriques sur le coeur des mammiferes. CR Acad Sci (Paris. 1899; 129: 1267–1268.
  4. Gallagher MM, Hennessy BJ, Edvardsson N, et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol. 2002; 40(5): 926–933.
  5. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011; 123(2): 131–136.
  6. Cappato R, Ezekowitz M, Klein A, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014; 35(47): 3346–3355.
  7. Flaker G, Lopes RD, Al-Khatib SM, et al. ARISTOTLE Committees and Investigators. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014; 63(11): 1082–1087.
  8. Kirchhof P, Benussi S, Kotecha D, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38): 2893–2962.
  9. Gawałko M, Kapłon-Cieślicka A, Budnik M, et al. Comparison of different oral anticoagulant regimens in patients with atrial fibrillation undergoing ablation or cardioversion. Pol Arch Intern Med. 2017; 127(12): 823–831.
  10. Frederiksen AS, Albertsen AE, Christesen AM, et al. Cardioversion of atrial fibrillation in a real-world setting: non-vitamin K antagonist oral anticoagulants ensure a fast and safe strategy compared to warfarin. Europace. 2018; 20(7): 1078–1085.
  11. Papp J, Zima E, Bover R, et al. Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry. Eur Heart J Cardiovasc Pharmacother. 2017; 3(3): 147–150.
  12. Coleman CM, Khalaf S, Mould S, et al. Novel oral anticoagulants for DC cardioversion procedures: utilization and cilnical outcomes compared with warfarin. Pacing Clin Electrophysiol. 2015; 38(6): 731–737.
  13. Cappato R, Ezekowitz M, Klein A, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014; 35(47): 3346–3355.
  14. Cozma D, Streian CG, Vacarescu C, et al. Back to sinus rhythm from atrial flutter or fibrillation: dabigatran is safe without transoesophageal control. Kardiol Pol. 2016; 74(5): 425–430.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl